Medical Devices · Published Aug 2026
Lithotripters Market
The global lithotripters market is projected to grow from USD 1.27 billion in 2025 to USD 2.16 billion by 2035, reflecting a CAGR of 5.5%. Key drivers include the rising prevalence of urolithiasis driven by sedentary lifestyles, dietary habits, and metabolic disorders such as diabetes and obesity. Technological advancements in lithotripters, particularly the development of compact and portable devices, are enhancing procedural accuracy and patient acceptability, supporting adoption across hospitals, ambulatory surgical centers, and clinics.
The market is segmented by product type, application, end user, technology, and distribution channel, with North America and Asia-Pacific representing significant growth opportunities due to developed healthcare infrastructure and high prevalence of kidney stones, respectively. However, complications associated with lithotripsy procedures and limitations in treating all types of kidney stones may restrain market expansion.
Market size
Growth trajectory through 2035
Lithotripters Market · Market size 2025–2035
Base year 2025 · Forecast 2035 · USD Billion
Source: Exactitude Consultancy analyst modeling. Anchor values from primary + secondary research; intermediate years interpolated from the CAGR trajectory. Full annual data pack included with the report.
What's new in this edition
Here's what changed
This edition rebased the forecast to 2025, added tracked developments through the last quarter, and re-cited every numeric claim against live public sources.
Recent developments tracked
-
Development 01 Technological Advancements
- Introduction of third-generation lithotripters with improved imaging integration and reduced procedural time, enhancing patient outcomes and procedural efficiency.
-
Development 02 Portable Lithotripters
- Development of compact and portable lithotripters by key players such as Siemens Medical Solutions and Karl Storz, enabling broader deployment in outpatient and remote healthcare settings.
-
Development 03 Strategic Partnerships
- Collaborations between manufacturers and healthcare providers to expand access to lithotripsy technologies, particularly in emerging markets.
-
Development 04 Regulatory Approvals
- Favorable regulatory approvals for new lithotripter models, supporting market penetration and innovation.
Emerging opportunities added
- Emerging markets expansion Rapidly growing healthcare infrastructure in Asia-Pacific, Latin America, and the Middle East & Africa presents significant opportunities for market penetration, particularly in countries with rising urolithiasis prevalence.
- Technological innovation in portable devices Continued advancements in portable and compact lithotripters are expected to enhance accessibility and adoption in outpatient and remote healthcare settings, driving demand.
- Integration with digital health platforms Adoption of connected lithotripters with telemedicine and remote monitoring capabilities can improve procedural efficiency and patient outcomes, creating new revenue streams.
- Focus on preventive care Increasing emphasis on early diagnosis and preventive measures for kidney stones, supported by public health campaigns, is likely to boost demand for lithotripsy as a primary treatment option.
Executive snapshot
The four things that matter
A condensed view of the market at a glance — sized, shaped, and pressure-tested against live public sources.
Market size · 2025–2035
forecast for 2035
- 2025 base
- $1.27 Bn
- CAGR
- 5.50%
- Expansion
- 1.7×
Market shape
top segment · 40.7% share
- Leading region
- Asia Pacific
- Top end-user
- Hospitals
- Top-5 concentration
- Low to medium · ~42%
Forces at play
▲ top tailwind
- ▼ headwind
- Procedure limitations
- Named players
- 15 profiled
- Growth peak
- 2027–2031
Latest development
Technological Advancements: Introduction of third-generation lithotripters with improved imaging integration and reduced procedural time, enhancing patient outcomes and procedural efficiency
+4 more tracked in this edition
Report scope
What this report answers
The specific decisions and questions covered in the 150-page report and its accompanying data pack — tailored to this market's segments, applications, and named competitors.
- How big is the Lithotripters Market today ($1.27 Bn base), and how fast will it grow at 5.5% CAGR through 2035?
- Which of Electrohydraulic Lithotripters, Laser Lithotripters, Extracorporeal Shock Wave Lithotripters holds the largest share, and how do the growth rates diverge?
- How is demand distributed across Kidney Stones, Ureter Stones, Bladder Stones applications, and which application is scaling fastest?
- How do North America, Europe, Asia-Pacific, Latin America compare on market share, growth rate, and regulatory posture?
- Where do Philips Healthcare, Medtronic plc, Abbott Laboratories and 12 other named players sit in market share, tier, and product breadth?
- What are the top growth drivers (led by Rising prevalence of urolithiasis) and top restraints (led by Procedure limitations), with quantified CAGR impact?
- What regulatory shifts and 5 tracked developments (2024–2025) materially affect the forecast?
- Which segments and geographies present the strongest investment thesis given the growth-window 2027–2031?
Market dynamics
Why the number moves this way
The forces expanding this market and the ones holding it back — each broken down into distinct, scannable points.
Growth drivers
Pulling the market up
- Rising prevalence of urolithiasis Increased incidence of kidney stones, driven by sedentary lifestyles, poor dietary habits, low water consumption, and metabolic disorders such as diabetes and obesity, is a primary driver of demand for lithotripsy procedures.
- Technological advancements in lithotripters Development of third-generation lithotripters, including compact and portable models, has improved procedural accuracy, reduced patient discomfort, and expanded deployment in hospitals and outpatient settings.
- Growing preference for minimally invasive procedures Lithotripsy offers a non-invasive alternative to traditional surgical interventions, with benefits such as reduced scarring, lower infection risk, and shorter recovery times, supporting higher adoption rates.
- Favorable reimbursement policies and healthcare initiatives Supportive reimbursement frameworks and government initiatives to improve healthcare infrastructure, particularly in emerging markets, are enhancing access to advanced lithotripsy technologies.
- Increasing healthcare expenditure and awareness Rising spending on healthcare services and greater awareness of early intervention for kidney stone management are contributing to market growth across both developed and developing regions.
Restraints
Holding it back
- Procedure limitations Lithotripsy is not effective for all types of kidney stones, particularly larger or harder stones, which may limit its applicability in certain patient populations.
- Potential complications Risks associated with lithotripsy, including incomplete stone fragmentation, tissue damage, and post-procedural complications, may deter adoption among some healthcare providers and patients.
- High initial costs and maintenance The capital expenditure required for advanced lithotripters and ongoing maintenance costs may pose financial barriers, particularly for smaller clinics and healthcare facilities in price-sensitive markets.
- Regulatory and approval delays Extended approval timelines for new lithotripter technologies and stringent regulatory requirements in certain regions may slow market penetration and innovation.
Trends
What we're watching
- Consolidation activity is accelerating as top players seek scale advantages; the report tracks named M&A + partnerships quarterly.
- Sustainability and traceability requirements are reshaping procurement criteria across enterprise buyers.
Impact analysis
Quantified drivers & restraints
Percentages are directional contributions to overall CAGR — not additive. Full sensitivity tables in the sample.
| Driver | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Rising prevalence of urolithiasis | +2.5% | Global | 2025–2035 |
| Technological advancements in lithotripters | +1.5% | Global | 2025–2035 |
| Growing preference for minimally invasive procedures | +1.2% | Global | 2025–2035 |
| Favorable reimbursement policies and healthcare initiatives | +0.8% | Global | 2025–2035 |
Restraints impact analysis
| Restraint | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Procedure limitations | −1.0% | Global | 2025–2029 |
| Potential complications | −0.7% | Global | 2025–2029 |
| High initial costs and maintenance | −0.5% | Global | 2025–2029 |
The lithotripters market is segmented by product type, application, end user, technology, and distribution channel.
Revenue share by type · 2025 base year
% OF $1.27 BN LITHOTRIPTERS MARKET · 4 TYPES COVERED
Each slice = that type's share of the total $1.27 Bn Lithotripters Market in 2025. Shares sum to 100%. Per-segment historicals + 2035 forecasts are in the report data pack.
By type
-
Electrohydraulic Lithotripters
-
Laser Lithotripters
-
Extracorporeal Shock Wave Lithotripters
By application
-
Kidney Stones
-
Ureter Stones
-
Bladder Stones
By technology
-
Technologies include Percutaneous Lithotripsy
-
Endoscopic Lithotripsy
By end-user industry
-
Hospitals
-
Urology Clinics
-
Research Institutions
-
Ambulatory Surgical Centers
By capacity
-
Channels include Direct Sales
-
Distributors
-
customer relationships
Geography
Regional market share
Base-year (2025) share by region. Growth rates through 2035 vary widely by market maturity — country-level detail sits in the report.
Regional share · 2025
SHARE OF $1.27 BN BASE MARKET
Bars sized to relative regional share. Leader region highlighted in gold.
Asia Pacific leads regional demand at ~37.7% in 2025. driven by manufacturing scale and end-market density
Per-region detail
-
North America
The region dominates the market due to a high prevalence of kidney stones, advanced healthcare infrastructure, and strong adoption of minimally invasive procedures. The U.S. market is particularly driven by rising incidence rates and favorable reimbursement policies
-
Europe
Growth is supported by developed healthcare systems and increasing awareness of non-invasive treatments. Countries such as Germany, the UK, and France are key contributors to market expansion
-
Asia-Pacific
The region is projected to exhibit the highest growth rate, driven by rising urolithiasis prevalence, improving healthcare access, and government initiatives to enhance healthcare infrastructure. China, Japan, and India are major markets in this region
-
Latin America
Growth is fueled by increasing healthcare expenditure and rising awareness of advanced lithotripsy technologies. Countries such as Brazil and Mexico are emerging as significant contributors
-
Middle East & Africa
The market is growing steadily, supported by improving healthcare facilities and rising prevalence of metabolic disorders. Countries such as Saudi Arabia and the UAE are key markets in this region
Competitive landscape
Who's competing, and how
The market is Low to Medium concentration. 15 named players are profiled in the report with product portfolios, financials where public, and recent strategic moves.
The lithotripters market is moderately consolidated, with leading players focusing on technological innovation, strategic partnerships, and geographic expansion to maintain their market position.
Concentration snapshot
Top 5 players control ~35–50% of the market
Estimated aggregate share of the top 5 by 2025 revenue. Named breakdown + individual shares in the full report.
Competitive tiers
Players are grouped into three tiers by revenue rank, product breadth, and strategic footprint. Full tier assignment in the report.
Tier 1 · Leaders
3companies
Global scale, integrated portfolio, brand recognition. Setting the pricing benchmark.
Tier 2 · Challengers
5companies
Regional strongholds, focused portfolio, actively expanding via M&A or capacity.
Tier 3 · Emerging
7companies
Niche or early-stage, differentiated technology or early-mover positioning.
Named players covered
Every profiled company includes market rank, base-year share, revenue estimate, HQ, product portfolio depth, and recent strategic moves. Unlock in the sample.
-
Philips Healthcare
Rank 01Share est. ~16%Revenue $■■■MHQ ■■■ -
Medtronic plc
Rank 02Share ■■.■%Revenue $■■■MHQ ■■■ -
Abbott Laboratories
Rank 03Share ■■.■%Revenue $■■■MHQ ■■■ -
Johnson & Johnson MedTech
Rank 04Share ■■.■%Revenue $■■■MHQ ■■■ -
Stryker Corporation
Rank 05Share ■■.■%Revenue $■■■MHQ ■■■ -
Becton, Dickinson and Company
Rank 06Share ■■.■%Revenue $■■■MHQ ■■■ -
Boston Scientific Corporation
Rank 07Share ■■.■%Revenue $■■■MHQ ■■■ -
Siemens Healthineers
Rank 08Share ■■.■%Revenue $■■■MHQ ■■■
+ 7 more player profiles in the full report.
Unlock the full competitive landscape
Per-player market share, revenue estimates, HQ, product portfolio depth, recent M&A + partnerships, and 3-tier ranking rationale — sample included.
Regulatory landscape
Policy and standards affecting the forecast
Material regulatory shifts across the major regional markets. The report tracks these quarter-by-quarter and quantifies their forecast impact.
-
United States
FDA classifies devices by risk (Class I/II/III). 510(k) clearances (~3000/year) require substantial equivalence; PMA approvals for high-risk devices. Quality System Regulation (QSR, 21 CFR 820) transitioning to ISO 13485 alignment 2026. UDI unique device identification mandatory. FDA cybersecurity guidance for connected devices.
-
European Union
Medical Device Regulation (MDR, EU 2017/745) fully applicable 2021 — significantly stricter than replaced MDD. IVDR (in vitro diagnostics) applicable 2022. Notified Body certification bottleneck: only 40 designated bodies for entire EU. Unique Device Identification (UDI) mandatory. EUDAMED database launching in phases.
-
China / APAC
NMPA (National Medical Products Administration) approves all devices for Chinese market; typical Class III timeline 2-3 years. Volume-based procurement (VBP) reduces device prices 40-90% for included categories. Japan's PMDA aligned with FDA on many pathways. India's CDSCO expanded device oversight since 2017.
-
Global standards
ISO 13485 quality management system certification held by 30K+ device manufacturers globally. ISO 14971 risk management mandatory in most jurisdictions. IMDRF (International Medical Device Regulators Forum) coordinates harmonisation across FDA, EMA, PMDA, NMPA, Health Canada, TGA, ANVISA.
Purchase options
License this report
All licenses include the full PDF report + Excel data pack + one analyst clarification call. Choose based on how many colleagues will need access.
Single user
$3,350
- 1 named user, non-transferable
- Full PDF + Excel data pack
- 1 hour analyst clarification call
Multi user
$4,950
- Up to 5 users at one location
- Full PDF + Excel data pack
- 2 hours analyst time
- Priority email support
Corporate
$6,950
- Unlimited users org-wide
- Full PDF + Excel data pack
- 4 hours analyst time
- Presentation-ready deck
Need custom scope, region cuts, or country-level detail? Request customization or speak to an analyst.
How buying works
- 01 Select a license — your enquiry reaches the desk lead within one business day.
- 02 Invoice issued — pay by wire transfer, corporate PO, or online (PayPal / Razorpay / cards). Preferred by most procurement teams.
- 03 Report delivered — full PDF + Excel data pack + analyst call slot in your inbox on receipt of payment.
Payment methods accepted
- PayPalGlobal
- RazorpayCards · UPI · Netbanking
- Visa · Mastercard · AmexVia gateway
- Wire transferUSD · EUR · INR · GBP
- Corporate PONet-30 on approval
Invoices raised in your billing currency. Enterprise procurement docs (W-9 / W-8BEN / VAT registration) available on request.
Methodology
How we built this estimate
Every number in this report is derived from three converging paths — primary interviews, top-down macro sizing, and bottom-up named-company revenue build-up — and re-verified against live public sources at each edition refresh.
-
Primary research
Structured analyst interviews with buyers, vendors, and distributors across the value chain — top-tier OEMs, mid-market integrators, and specialised suppliers. Respondent distribution is disclosed in the sample so readers can weight the mix themselves.
-
Secondary research
Company filings, trade association reports, government statistics, and paid databases feed the top-down macro layer. Every source is footnoted in the report so any downstream reader can retrace how a number was arrived at.
-
Data triangulation
Three independent estimation paths — top-down macro sizing, bottom-up named-company build-up, and cross-check against installed-base or shipment proxies — converge to a single defensible number. Divergences greater than 8% trigger a re-review.
-
Analyst review
Every model is pressure-tested by a senior analyst before publication. Assumptions are stated explicitly, sensitivities are documented, and the accompanying Excel data pack lets clients replicate every calculation on their own inputs.
Frequently asked questions
Common questions about this report
-
How big is the Lithotripters Market in 2025?
The Lithotripters Market is estimated at approximately $1.27 Bn in 2025, based on triangulated bottom-up revenue and top-down macro modelling. Full annual data in the report data pack.
-
What's the forecast growth rate through 2035?
The market is projected to grow at a 5.50% CAGR from 2025 to 2035, reaching $2.17 Bn by 2035. This reflects a mix of end-user demand growth, regulatory tailwinds, and technology cost-decline. Sensitivity tables in the sample.
-
Which region leads the market?
Asia Pacific leads the market, accounting for approximately 37.7% of 2025 revenue. Country-level detail is broken out in the report.
-
Which segment leads the market?
Electrohydraulic Lithotripters leads the type segmentation with an estimated 40.7% share. See the Segments section for the full breakdown across type, application, technology, and end-user.
-
Who are the major players covered?
The report profiles 15 named players including Philips Healthcare, Medtronic plc, Abbott Laboratories, Johnson & Johnson MedTech, Stryker Corporation, and others. Each profile covers product portfolio, financials where public, and recent strategic moves.
-
What's driving growth in this market?
The top growth driver is Rising prevalence of urolithiasis. Increased incidence of kidney stones, driven by sedentary lifestyles, poor dietary habits, low water consumption, and metabolic disorders such as diabetes and obesity, is a primary driver of demand for lithotripsy procedures.
-
What are the main restraints?
The primary restraint is Procedure limitations. Lithotripsy is not effective for all types of kidney stones, particularly larger or harder stones, which may limit its applicability in certain patient populations.
-
What are the most recent developments?
Recent notable events include: : Technological Advancements: Introduction of third-generation lithotripters with improved imaging integration and reduced procedural time, enhancing patient outcomes and procedural efficiency; : Portable Lithotripters: Development of compact and portable lithotripters by key players such as Siemens Medical Solutions and Karl Storz, enabling broader deployment in outpatient and remote healthcare settings; : Strategic Partnerships: Collaborations between manufacturers and healthcare providers to expand access to lithotripsy technologies, particularly in emerging markets. Full timeline in the report.
-
Can I customise the scope?
Yes. We regularly customise reports for regional cuts, country-level detail, additional segment axes, or specific company profiles. Request customization here and an analyst will scope it with you within one business day.
The Lithotripters Market is projected to reach $2.17 Bn by 2035, up from $1.27 Bn in 2025 — a 5.50% CAGR equating to roughly 1.7× expansion. The bars anchor both endpoints so you can pressure-test the trajectory against your own assumptions.